This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
RedHill Biopharma Ltd., a biopharmaceutical company, focuses on the development and acquisition of late clinical-stage, proprietary, and orally-administered drugs for the treatment of inflammatory and gastrointestinal diseases, including gastrointestinal cancers in Israel.View RDHL key stats
Redhill Biopharma Ltd - RDHL - EQUITY
Reviewed By: TheStreet Ratings on .
Report Summary: TheStreet Ratings team rates Redhill Biopharma Ltd as a
Hold with a ratings score of C-.
Report Snippet: We rate REDHILL BIOPHARMA LTD (RDHL) a HOLD. The primary factors that have impacted our rating are mixed - some indicating strength, some showing weaknesses, with little evidence to justify the expectation of either a positive or negative performance for this stock relative to most other stocks. Among the primary strengths of the company is its solid financial position based on a variety of debt and liquidity measures that we have evaluated. At the same time, however, we also find weaknesses including deteriorating net income, disappointing return on equity and weak operating cash flow.